Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.57 |
| ▸ | JAK1 | P23458 | 17/20 | 0.57 |
| ▸ | TYK2 | P29597 | 17/20 | 0.57 |
| ▸ | JAK3 | P52333 | 12/20 | 0.57 |
| ▸ | BTK | Q06187 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19299855 | 0.84 | JAK2 (0.56) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL22449677 | 0.84 | JAK2 (0.73) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL17816063 | 0.82 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL17801124 | 0.81 | JAK2 (0.57) | JAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL31201717 | 0.81 | JAK2 (0.57) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25512929 | 0.81 | JAK2 (0.54) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL24437611 | 0.80 | BTK (0.56) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL24438288 | 0.79 | BTK (0.53) | JAK2JAK1TYK2JAK3BTK | |
| SCHEMBL24438739 | 0.79 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL24438956 | 0.79 | JAK2 (0.52) | JAK2JAK1TYK2JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12404275-B2 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-118804915-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4429770-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-113924301-B | Pyrazolopyrazine derivative compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3419978-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CBR1 | JAK2 849/4885JAK1 1320/4885TYK2 1885/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 286/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | JAK2 923/4885JAK1 1401/4885TYK2 1835/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | JAK2 6/4885JAK1 7/4885TYK2 12/4885 |
| US-12404275-B2 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof | JAK2, TYK2, JAK1 | JAK2 1/4885JAK1 3/4885TYK2 2/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | JAK2 923/4885JAK1 1401/4885TYK2 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.